New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - moxifloxacin hydrochloride 436.8mg equivalent to 400 mg moxifloxacin - solution for infusion - 400 mg - active: moxifloxacin hydrochloride 436.8mg equivalent to 400 mg moxifloxacin excipient: hydrochloric acid sodium chloride sodium hydroxide water for injection - avelox tablets and solution for infusion is indicated for the treatment of the following bacterial infections caused by susceptible strains: · complicated intra-abdominal infections including polymicrobial infections such as abscesses

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - moxifloxacin, quantity: 400 mg (equivalent: moxifloxacin hydrochloride, qty 436.8 mg) - tablet, film coated - excipient ingredients: titanium dioxide; microcrystalline cellulose; hypromellose; ferric oxide; croscarmellose sodium; lactose monohydrate; magnesium stearate; macrogol 400 - avelox (moxifloxacin hydrochloride) tablets are indicated for the treatment of adults with infections caused by susceptible organisms in the conditions. acute bacterial sinusitis, community acquired pneumonia, acute exacerbations of chronic bronchitis. avelox iv (moxifloxacin hydrochloride) intravenous solutions are indicated for treatment of adults who require initial iv therapy for the treatment of infections in the conditions. community acquired pneumonia (caused by susceptible organisms). acute exacerbations of chronic bronchitis when caused by organisms bacteriologically proven to be resistant to other classes of antibiotics or when there is intolerance to other antibiotics. avelox iv (moxifloxacin hydrochloride) intravenous solutions are indicated for treatment of adults with severe and complicated skin and skin structure infections who require initial parenteral therapy, and who have intolerance to alternative agents. (especially penicillin allergy), and when caused by organisms known to be susceptible

Ireland - English - HPRA (Health Products Regulatory Authority)

virbac s.a. - eprinomectin - pour-on solution - 5 mg/ml - eprinomectin - bovine - endectoparasiticides

United Kingdom - English - VMD (Veterinary Medicines Directorate)

virbac - eprinomectin - pour-on solution - endectocide - cattle

United States - English - NLM (National Library of Medicine)

cardinal health - moxifloxacin hydrochloride (unii: c53598599t) (moxifloxacin - unii:u188xyd42p) - moxifloxacin 400 mg

United States - English - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - moxifloxacin hydrochloride (unii: c53598599t) (moxifloxacin - unii:u188xyd42p) - moxifloxacin 400 mg

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

bayer -

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

bayer -

United States - English - NLM (National Library of Medicine)

redpharm drug inc. - moxifloxacin hydrochloride (unii: c53598599t) (moxifloxacin - unii:u188xyd42p) - moxifloxacin hydrochloride 400 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of avelox and other antibacterial drugs, avelox should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. avelox  tablets and iv are indicated for the treatment of adults (≥ 18 years of age) with infections caused by susceptible strains of the designated microorganisms in the conditions listed below [see dosage and administration (2) and use in specific populations (8.5)]. culture and susceptibility testing appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to moxifloxacin

Ireland - English - HPRA (Health Products Regulatory Authority)

virbac s.a. - deltamethrin - cutaneous solution - 10 mg/ml - deltamethrin - bovine, ovine - ectoparasiticide